National Immunoglobulin Database Meeting Procurement Update 9th December 2016 DH – Leading the nation’s health and care Commercial Medicines Unit

Role of CMU Deliver efficiencies for the NHS and DH in the procurement of medicines Initiate procurement and support the DH purchasing for safety  agenda of those medicines Ensure an efficient and effective supply chain of medicines to the patient Analysis and interpretation of data (Pharmex) Homecare, Branded, Generics, Specialised, Vaccines / Emergency Planning Products & Services list www.gov.uk/government/collections/commercial-medicines-unit-cmu Move to NHS England DH – Leading the nation’s health and care Commercial Medicines Unit

Current Framework update 1 June 2013 to 31 May 2015 (extended to 28 Feb 2017) Further extension by 3 months Framework covering England and N Ireland £162 million per annum expenditure 5.4 million grams of Immunoglobulin p.a. Price per gram paid reduced 6.84% 2011 to 2016 Management / communication of supply issues One brand represent 55% of IVIG market share Business case for next framework Separate framework tendered for albumin & anti-D IG DH – Leading the nation’s health and care

Summary of Annual Immunoglobulin Sales 2011 – 2016 (England and N Ireland) Grams Usage: To show simple data relationships in various categories How-to: Right click on the graph to edit the data (adding categories, additional bars etc) Always make sure that both axis are appropriately labelled, with units Add data labels where possible/appropriate (remove them if the slide becomes too busy/unreadable) Use consistent, complimentary colours in the graph Ensure there is an accurate legend Add footnotes if required, delete the notes box if not required

Previous tender No guaranteed volumes Requested volumes based on scoring assessment 51% price 15% product volumes 15% quality (packaging, shelf-life, infusion times, bar-coding) 13% contingency 6% service DH – Leading the nation’s health and care

Next tender considerations: Incorporating volume bands? Management of market share? How this would work alongside Clinical Guidelines for use – existing LT patients, new LT patients, ST treatments New products now in market and/or on horizon – do we want all on the framework? Additional considerations regarding Homecare use? Increasing use of 10% IVIG product Impacts of Brexit / DH Statutory Scheme changes Overhaul weightings and scoring accordingly DH – Leading the nation’s health and care

Stakeholder input Any comments or considerations for tender strategy Direct or indirect input into the tender process Does the forecasting process work? Representation from clinical, nursing, homecare, commissioning, patient group and pharmacy Ongoing engagement with industry prior to tender issue Stakeholder engagement – December / January Tender issue February Evaluation and award March/April Start 1 June 2017 DH – Leading the nation’s health and care

Contact Details If any queries regarding framework or interest in being involved in the next tender process: David Ford david.ford@dh.gsi.gov.uk Tel. 01928 755224 DH – Leading the nation’s health and care